CovidSeniorV1, Main, Exploration, bibRecord, 000707

Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.

Identifieur interne : 000707 ( Main/Exploration ); précédent : 000706; suivant : 000708

Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.

Auteurs : Fernando Montero [Espagne] ; Julia Martínez-Barrio [Espagne] ; Belén Serrano-Benavente [Espagne] ; Teresa González [Espagne] ; Javier Rivera [Espagne] ; Juan Molina Collada [Espagne] ; Isabel Castrej N [Espagne] ; Jose Álvaro-Gracia [Espagne]

Source :

Rheumatology international [ 1437-160X ] ; 2020.

RBID : pubmed:32794113

Descripteurs français

English descriptors

KwdEn :
- Aged (MeSH), Anti-Bacterial Agents (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Antiviral Agents (therapeutic use), Arthritis, Psoriatic (complications), Arthritis, Psoriatic (drug therapy), Arthritis, Psoriatic (epidemiology), Arthritis, Rheumatoid (complications), Arthritis, Rheumatoid (drug therapy), Arthritis, Rheumatoid (epidemiology), Autoimmune Diseases (complications), Autoimmune Diseases (drug therapy), Autoimmune Diseases (epidemiology), Azithromycin (therapeutic use), Betacoronavirus (MeSH), Comorbidity (MeSH), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (mortality), Coronavirus Infections (physiopathology), Coronavirus Infections (therapy), Drug Combinations (MeSH), Female (MeSH), Glucocorticoids (therapeutic use), Hospitalization (statistics & numerical data), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunosuppressive Agents (therapeutic use), Logistic Models (MeSH), Lopinavir (therapeutic use), Lung Diseases (epidemiology), Lupus Erythematosus, Systemic (complications), Lupus Erythematosus, Systemic (drug therapy), Lupus Erythematosus, Systemic (epidemiology), Male (MeSH), Middle Aged (MeSH), Multivariate Analysis (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (mortality), Pneumonia, Viral (physiopathology), Pneumonia, Viral (therapy), Retrospective Studies (MeSH), Ritonavir (therapeutic use), Severity of Illness Index (MeSH), Sex Factors (MeSH), Spain (epidemiology).
MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Antiviral Agents, Azithromycin, Glucocorticoids, Hydroxychloroquine, Immunosuppressive Agents, Lopinavir, Ritonavir.
- geographic , epidemiology : Spain.
- complications : Arthritis, Psoriatic, Arthritis, Rheumatoid, Autoimmune Diseases, Coronavirus Infections, Lupus Erythematosus, Systemic, Pneumonia, Viral.
- drug therapy : Arthritis, Psoriatic, Arthritis, Rheumatoid, Autoimmune Diseases, Coronavirus Infections, Lupus Erythematosus, Systemic.
- epidemiology : Arthritis, Psoriatic, Arthritis, Rheumatoid, Autoimmune Diseases, Lung Diseases, Lupus Erythematosus, Systemic.
- mortality : Coronavirus Infections, Pneumonia, Viral.
- physiopathology : Coronavirus Infections, Pneumonia, Viral.
- statistics & numerical data : Hospitalization.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Aged, Betacoronavirus, Comorbidity, Drug Combinations, Female, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Pandemics, Retrospective Studies, Severity of Illness Index, Sex Factors.

Abstract

OBJECTIVE

To describe clinical characteristics of patients with rheumatic and musculoskeletal diseases (RMDs) and immunosuppressive therapies with Coronavirus disease 2019 (COVID-19) at an academic rheumatology center in Madrid and to identify baseline variables associated with a severe infection requiring hospitalization.

METHODS

We identified SARS-CoV-2 positive cases by polymerase chain reaction performed at our center within an updated RMDs database in our clinic. Additional RMDs patients were identified when they contacted the clinic because of a positive infection. Data extraction included diagnosis, demographics, immunosuppressive treatment, comorbidities, and laboratory tests. Comparisons between patients with or without hospitalization were performed. Multivariate logistic regression was used to analyze associations between baseline variables and need for hospitalization.

RESULTS

A total of 62 patients with COVID-19 and underlying RMDs were identified by April 24, 2020. Median age was 60.9 years, and 42% men. Forty-two patients required hospitalization; these were more frequently men, older and with comorbidities. There were no statistically significant between-group differences for rheumatologic diagnosis and for baseline use of immunosuppressive therapy except for glucocorticoids that were more frequent in hospitalized patients. Total deaths were 10 (16%) patients. In multivariate analysis, male sex (odds ratio [OR], 8.63; p = 0.018), previous lung disease (OR, 27.47; p = 0.042), and glucocorticoids use (> 5 mg/day) (OR, 9.95; p = 0.019) were significantly associated to hospitalization.

CONCLUSION

Neither specific RMD diagnoses or exposures to DMARDs were associated with increased odds of hospitalization. Being male, previous lung disease and exposure to glucocorticoids were associated with higher odds of hospitalization in RMDs patients.

DOI: 10.1007/s00296-020-04676-4
PubMed: 32794113
PubMed Central: PMC7425254

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000659
to stream Main, to step Curation: 000659

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.</title>
<author><name sortKey="Montero, Fernando" sort="Montero, Fernando" uniqKey="Montero F" first="Fernando" last="Montero">Fernando Montero</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain. fernandojose.montero@salud.madrid.org.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Martinez Barrio, Julia" sort="Martinez Barrio, Julia" uniqKey="Martinez Barrio J" first="Julia" last="Martínez-Barrio">Julia Martínez-Barrio</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Serrano Benavente, Belen" sort="Serrano Benavente, Belen" uniqKey="Serrano Benavente B" first="Belén" last="Serrano-Benavente">Belén Serrano-Benavente</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gonzalez, Teresa" sort="Gonzalez, Teresa" uniqKey="Gonzalez T" first="Teresa" last="González">Teresa González</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rivera, Javier" sort="Rivera, Javier" uniqKey="Rivera J" first="Javier" last="Rivera">Javier Rivera</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Molina Collada, Juan" sort="Molina Collada, Juan" uniqKey="Molina Collada J" first="Juan" last="Molina Collada">Juan Molina Collada</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Castrej N, Isabel" sort="Castrej N, Isabel" uniqKey="Castrej N I" first="Isabel" last="Castrej N">Isabel Castrej N</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alvaro Gracia, Jose" sort="Alvaro Gracia, Jose" uniqKey="Alvaro Gracia J" first="Jose" last="Álvaro-Gracia">Jose Álvaro-Gracia</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32794113</idno>
<idno type="pmid">32794113</idno>
<idno type="doi">10.1007/s00296-020-04676-4</idno>
<idno type="pmc">PMC7425254</idno>
<idno type="wicri:Area/Main/Corpus">000659</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000659</idno>
<idno type="wicri:Area/Main/Curation">000659</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000659</idno>
<idno type="wicri:Area/Main/Exploration">000659</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.</title>
<author><name sortKey="Montero, Fernando" sort="Montero, Fernando" uniqKey="Montero F" first="Fernando" last="Montero">Fernando Montero</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain. fernandojose.montero@salud.madrid.org.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Martinez Barrio, Julia" sort="Martinez Barrio, Julia" uniqKey="Martinez Barrio J" first="Julia" last="Martínez-Barrio">Julia Martínez-Barrio</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Serrano Benavente, Belen" sort="Serrano Benavente, Belen" uniqKey="Serrano Benavente B" first="Belén" last="Serrano-Benavente">Belén Serrano-Benavente</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gonzalez, Teresa" sort="Gonzalez, Teresa" uniqKey="Gonzalez T" first="Teresa" last="González">Teresa González</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rivera, Javier" sort="Rivera, Javier" uniqKey="Rivera J" first="Javier" last="Rivera">Javier Rivera</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Molina Collada, Juan" sort="Molina Collada, Juan" uniqKey="Molina Collada J" first="Juan" last="Molina Collada">Juan Molina Collada</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Castrej N, Isabel" sort="Castrej N, Isabel" uniqKey="Castrej N I" first="Isabel" last="Castrej N">Isabel Castrej N</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alvaro Gracia, Jose" sort="Alvaro Gracia, Jose" uniqKey="Alvaro Gracia J" first="Jose" last="Álvaro-Gracia">Jose Álvaro-Gracia</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Rheumatology international</title>
<idno type="eISSN">1437-160X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term>
<term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Antirheumatic Agents (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Arthritis, Psoriatic (complications)</term>
<term>Arthritis, Psoriatic (drug therapy)</term>
<term>Arthritis, Psoriatic (epidemiology)</term>
<term>Arthritis, Rheumatoid (complications)</term>
<term>Arthritis, Rheumatoid (drug therapy)</term>
<term>Arthritis, Rheumatoid (epidemiology)</term>
<term>Autoimmune Diseases (complications)</term>
<term>Autoimmune Diseases (drug therapy)</term>
<term>Autoimmune Diseases (epidemiology)</term>
<term>Azithromycin (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Comorbidity (MeSH)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (mortality)</term>
<term>Coronavirus Infections (physiopathology)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Drug Combinations (MeSH)</term>
<term>Female (MeSH)</term>
<term>Glucocorticoids (therapeutic use)</term>
<term>Hospitalization (statistics & numerical data)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Logistic Models (MeSH)</term>
<term>Lopinavir (therapeutic use)</term>
<term>Lung Diseases (epidemiology)</term>
<term>Lupus Erythematosus, Systemic (complications)</term>
<term>Lupus Erythematosus, Systemic (drug therapy)</term>
<term>Lupus Erythematosus, Systemic (epidemiology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Multivariate Analysis (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (mortality)</term>
<term>Pneumonia, Viral (physiopathology)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Ritonavir (therapeutic use)</term>
<term>Severity of Illness Index (MeSH)</term>
<term>Sex Factors (MeSH)</term>
<term>Spain (epidemiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term>
<term>Analyse multifactorielle (MeSH)</term>
<term>Antibactériens (usage thérapeutique)</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Antirhumatismaux (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Arthrite psoriasique (complications)</term>
<term>Arthrite psoriasique (traitement médicamenteux)</term>
<term>Arthrite psoriasique (épidémiologie)</term>
<term>Association médicamenteuse (MeSH)</term>
<term>Azithromycine (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Comorbidité (MeSH)</term>
<term>Espagne (épidémiologie)</term>
<term>Facteurs sexuels (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Glucocorticoïdes (usage thérapeutique)</term>
<term>Hospitalisation (statistiques et données numériques)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Immunosuppresseurs (usage thérapeutique)</term>
<term>Indice de gravité de la maladie (MeSH)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (mortalité)</term>
<term>Infections à coronavirus (physiopathologie)</term>
<term>Infections à coronavirus (thérapie)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Lopinavir (usage thérapeutique)</term>
<term>Lupus érythémateux disséminé (complications)</term>
<term>Lupus érythémateux disséminé (traitement médicamenteux)</term>
<term>Lupus érythémateux disséminé (épidémiologie)</term>
<term>Maladies auto-immunes (complications)</term>
<term>Maladies auto-immunes (traitement médicamenteux)</term>
<term>Maladies auto-immunes (épidémiologie)</term>
<term>Maladies pulmonaires (épidémiologie)</term>
<term>Modèles logistiques (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (mortalité)</term>
<term>Pneumopathie virale (physiopathologie)</term>
<term>Pneumopathie virale (thérapie)</term>
<term>Polyarthrite rhumatoïde (complications)</term>
<term>Polyarthrite rhumatoïde (traitement médicamenteux)</term>
<term>Polyarthrite rhumatoïde (épidémiologie)</term>
<term>Ritonavir (usage thérapeutique)</term>
<term>Sujet âgé (MeSH)</term>
<term>Études rétrospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Antirheumatic Agents</term>
<term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Glucocorticoids</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Arthritis, Psoriatic</term>
<term>Arthritis, Rheumatoid</term>
<term>Autoimmune Diseases</term>
<term>Coronavirus Infections</term>
<term>Lupus Erythematosus, Systemic</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Psoriatic</term>
<term>Arthritis, Rheumatoid</term>
<term>Autoimmune Diseases</term>
<term>Coronavirus Infections</term>
<term>Lupus Erythematosus, Systemic</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Arthritis, Psoriatic</term>
<term>Arthritis, Rheumatoid</term>
<term>Autoimmune Diseases</term>
<term>Lung Diseases</term>
<term>Lupus Erythematosus, Systemic</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Hospitalisation</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Arthrite psoriasique</term>
<term>Infections à coronavirus</term>
<term>Lupus érythémateux disséminé</term>
<term>Maladies auto-immunes</term>
<term>Polyarthrite rhumatoïde</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Antirhumatismaux</term>
<term>Antiviraux</term>
<term>Arthrite psoriasique</term>
<term>Azithromycine</term>
<term>Glucocorticoïdes</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Infections à coronavirus</term>
<term>Lopinavir</term>
<term>Lupus érythémateux disséminé</term>
<term>Maladies auto-immunes</term>
<term>Pneumopathie virale</term>
<term>Polyarthrite rhumatoïde</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Arthrite psoriasique</term>
<term>Espagne</term>
<term>Lupus érythémateux disséminé</term>
<term>Maladies auto-immunes</term>
<term>Maladies pulmonaires</term>
<term>Polyarthrite rhumatoïde</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Betacoronavirus</term>
<term>Comorbidity</term>
<term>Drug Combinations</term>
<term>Female</term>
<term>Humans</term>
<term>Logistic Models</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multivariate Analysis</term>
<term>Pandemics</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Sex Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Analyse multifactorielle</term>
<term>Association médicamenteuse</term>
<term>Betacoronavirus</term>
<term>Comorbidité</term>
<term>Facteurs sexuels</term>
<term>Femelle</term>
<term>Humains</term>
<term>Indice de gravité de la maladie</term>
<term>Modèles logistiques</term>
<term>Mâle</term>
<term>Pandémies</term>
<term>Sujet âgé</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>To describe clinical characteristics of patients with rheumatic and musculoskeletal diseases (RMDs) and immunosuppressive therapies with Coronavirus disease 2019 (COVID-19) at an academic rheumatology center in Madrid and to identify baseline variables associated with a severe infection requiring hospitalization.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>We identified SARS-CoV-2 positive cases by polymerase chain reaction performed at our center within an updated RMDs database in our clinic. Additional RMDs patients were identified when they contacted the clinic because of a positive infection. Data extraction included diagnosis, demographics, immunosuppressive treatment, comorbidities, and laboratory tests. Comparisons between patients with or without hospitalization were performed. Multivariate logistic regression was used to analyze associations between baseline variables and need for hospitalization.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>A total of 62 patients with COVID-19 and underlying RMDs were identified by April 24, 2020. Median age was 60.9 years, and 42% men. Forty-two patients required hospitalization; these were more frequently men, older and with comorbidities. There were no statistically significant between-group differences for rheumatologic diagnosis and for baseline use of immunosuppressive therapy except for glucocorticoids that were more frequent in hospitalized patients. Total deaths were 10 (16%) patients. In multivariate analysis, male sex (odds ratio [OR], 8.63; p = 0.018), previous lung disease (OR, 27.47; p = 0.042), and glucocorticoids use (> 5 mg/day) (OR, 9.95; p = 0.019) were significantly associated to hospitalization.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Neither specific RMD diagnoses or exposures to DMARDs were associated with increased odds of hospitalization. Being male, previous lung disease and exposure to glucocorticoids were associated with higher odds of hospitalization in RMDs patients.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32794113</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>40</Volume>
<Issue>10</Issue>
<PubDate><Year>2020</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Rheumatology international</Title>
<ISOAbbreviation>Rheumatol Int</ISOAbbreviation>
</Journal>
<ArticleTitle>Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.</ArticleTitle>
<Pagination><MedlinePgn>1593-1598</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-020-04676-4</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe clinical characteristics of patients with rheumatic and musculoskeletal diseases (RMDs) and immunosuppressive therapies with Coronavirus disease 2019 (COVID-19) at an academic rheumatology center in Madrid and to identify baseline variables associated with a severe infection requiring hospitalization.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We identified SARS-CoV-2 positive cases by polymerase chain reaction performed at our center within an updated RMDs database in our clinic. Additional RMDs patients were identified when they contacted the clinic because of a positive infection. Data extraction included diagnosis, demographics, immunosuppressive treatment, comorbidities, and laboratory tests. Comparisons between patients with or without hospitalization were performed. Multivariate logistic regression was used to analyze associations between baseline variables and need for hospitalization.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 62 patients with COVID-19 and underlying RMDs were identified by April 24, 2020. Median age was 60.9 years, and 42% men. Forty-two patients required hospitalization; these were more frequently men, older and with comorbidities. There were no statistically significant between-group differences for rheumatologic diagnosis and for baseline use of immunosuppressive therapy except for glucocorticoids that were more frequent in hospitalized patients. Total deaths were 10 (16%) patients. In multivariate analysis, male sex (odds ratio [OR], 8.63; p = 0.018), previous lung disease (OR, 27.47; p = 0.042), and glucocorticoids use (> 5 mg/day) (OR, 9.95; p = 0.019) were significantly associated to hospitalization.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Neither specific RMD diagnoses or exposures to DMARDs were associated with increased odds of hospitalization. Being male, previous lung disease and exposure to glucocorticoids were associated with higher odds of hospitalization in RMDs patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montero</LastName>
<ForeName>Fernando</ForeName>
<Initials>F</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0003-4594-7663</Identifier>
<AffiliationInfo><Affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain. fernandojose.montero@salud.madrid.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martínez-Barrio</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-9670-1746</Identifier>
<AffiliationInfo><Affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Serrano-Benavente</LastName>
<ForeName>Belén</ForeName>
<Initials>B</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0001-7805-1359</Identifier>
<AffiliationInfo><Affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>González</LastName>
<ForeName>Teresa</ForeName>
<Initials>T</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0003-4713-0737</Identifier>
<AffiliationInfo><Affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rivera</LastName>
<ForeName>Javier</ForeName>
<Initials>J</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0001-8147-5881</Identifier>
<AffiliationInfo><Affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Molina Collada</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0001-5191-7802</Identifier>
<AffiliationInfo><Affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Castrejón</LastName>
<ForeName>Isabel</ForeName>
<Initials>I</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0003-1811-2417</Identifier>
<AffiliationInfo><Affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Álvaro-Gracia</LastName>
<ForeName>Jose</ForeName>
<Initials>J</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-0343-3747</Identifier>
<AffiliationInfo><Affiliation>Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>08</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Rheumatol Int</MedlineTA>
<NlmUniqueID>8206885</NlmUniqueID>
<ISSNLinking>0172-8172</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>I031V2H011</RegistryNumber>
<NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015535" MajorTopicYN="N">Arthritis, Psoriatic</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008171" MajorTopicYN="N">Lung Diseases</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune diseases</Keyword>
<Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Poor outcomes</Keyword>
<Keyword MajorTopicYN="N">Rheumatology</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>06</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>08</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32794113</ArticleId>
<ArticleId IdType="doi">10.1007/s00296-020-04676-4</ArticleId>
<ArticleId IdType="pii">10.1007/s00296-020-04676-4</ArticleId>
<ArticleId IdType="pmc">PMC7425254</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2020 Feb 20;382(8):727-733</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 May 15;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32414804</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2020 Mar 13;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med. 2020 May;46(5):846-848</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32125452</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterology. 2020 Aug;159(2):481-491.e3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32425234</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Jun;582(7813):469</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32546811</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jun;80(6):607-613</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):473-475</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32043983</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 Sep;79(9):1156-1162</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32457048</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Rheumatol. 2020 May;2(5):e250-e253</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32309814</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 Jun;79(6):839-840</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 Sep;79(9):1170-1173</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32532753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 May;79(5):667-668</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32241793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Arthritis Rheum. 2020 Aug;50(4):564-570</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32425260</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jul 2;383(1):85-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32348641</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
</country>
<region><li>Communauté de Madrid</li>
</region>
<settlement><li>Madrid</li>
</settlement>
</list>
<tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Montero, Fernando" sort="Montero, Fernando" uniqKey="Montero F" first="Fernando" last="Montero">Fernando Montero</name>
</region>
<name sortKey="Alvaro Gracia, Jose" sort="Alvaro Gracia, Jose" uniqKey="Alvaro Gracia J" first="Jose" last="Álvaro-Gracia">Jose Álvaro-Gracia</name>
<name sortKey="Castrej N, Isabel" sort="Castrej N, Isabel" uniqKey="Castrej N I" first="Isabel" last="Castrej N">Isabel Castrej N</name>
<name sortKey="Gonzalez, Teresa" sort="Gonzalez, Teresa" uniqKey="Gonzalez T" first="Teresa" last="González">Teresa González</name>
<name sortKey="Martinez Barrio, Julia" sort="Martinez Barrio, Julia" uniqKey="Martinez Barrio J" first="Julia" last="Martínez-Barrio">Julia Martínez-Barrio</name>
<name sortKey="Molina Collada, Juan" sort="Molina Collada, Juan" uniqKey="Molina Collada J" first="Juan" last="Molina Collada">Juan Molina Collada</name>
<name sortKey="Rivera, Javier" sort="Rivera, Javier" uniqKey="Rivera J" first="Javier" last="Rivera">Javier Rivera</name>
<name sortKey="Serrano Benavente, Belen" sort="Serrano Benavente, Belen" uniqKey="Serrano Benavente B" first="Belén" last="Serrano-Benavente">Belén Serrano-Benavente</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000707 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000707 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidSeniorV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32794113
   |texte=   Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32794113" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidSeniorV1

This area was generated with Dilib version V0.6.37.
Data generation: Thu Oct 15 09:49:45 2020. Site generation: Wed Jan 27 17:10:23 2021

	Serveur d'exploration sur la COVID chez les séniors
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID chez les séniors

Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.

Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki